• 

  The Gut Microbiome in Aging and Cognitive Health
• 

  Some Alzheimer’s, Parkinson’s Therapies May Cause Brain Inflammation
• 

  Renewed Interest for Galantamine, an 18-Year-Old Alzheimer’s Drug
• 

  9/10 Alzheimer’s Patients Lose Sense of Smell—Is Beta-Amyloid the Culprit?
• 

  ‘Some Hope Over No Hope:’ A Retired Doctor on Alzheimer’s Diagnosis and the Aduhelm Trial
• 

  New Alzheimer’s Prediction Smartphone App Gets FDA Breakthrough Status
• 

  Alzheimer’s Disease: Five Common Myths to Dispel
• 

  Seeking Physical Exercise’s Brain Health Benefits in Saunas and Hot Tubs
• 

  Bio-Hermes Study Underway To Develop Cost-Effective Alzheimer’s Diagnostics
• 

  To Be Truly Dementia-Friendly, Communities Must Be Dementia-Inclusive
• 

  COVID-19 May Hasten Alzheimer’s Symptoms
• 

  Transgender and Nonbinary Adults More Likely to Develop Alzheimer’s Symptoms
• 

  Meet Lilly’s Investigational Alzheimer’s Drug Donanemab: A Q&A With Dr. David Weidman
• 

  Neuroscientist Daniela Kaufer: Aging, Disease, and the Blood-Brain Barrier
• 

  Some Hospitals Refuse to Offer Alzheimer’s Drug Aduhelm

Previous202122Next